Archive · 20 Aug 2025
Rubicon Research Files Addendum, IPO Launch Imminent
Imagine a company called Rubicon Research that makes medicines.
They're planning to sell shares to the public for the first time, like a big lemonade stand.
They updated their paperwork to show how well they're doing!
Their income and profits have grown a lot in just a few years.
A company bought some shares ahead of the public offering.
They plan to use the money to pay off debts, buy other companies, and grow.
They recently purchased a factory to make more medicine.
The government has approved the sale of shares, and they'll be listed on the stock market soon.
Rubicon Research filed an addendum to its DRHP with SEBI, updating financial data.
Operating income tripled in three years, reaching Rs 1,284.27 crore in FY25.
EBITDA grew six-fold, with a reported figure of Rs 267.8 crore in FY25.
The company completed a Rs 250 crore pre-IPO placement with Amansa Investments Ltd.
Rubicon acquired Alkem Laboratories' manufacturing facility in Pithampur for Rs 149 crore.
- Who
- Rubicon Research, a pharmaceutical formulations company.
- What
- Rubicon Research filed an addendum to its DRHP with SEBI and plans an IPO.
- When
- FY25 and Q1 FY26 for financial data; IPO launch imminent.
- Where
- India; shares to be listed on BSE and NSE.
- Why
- To raise capital for debt repayment, acquisitions, and strategic initiatives.
- Operating Income (FY25)
- Rs 1,284.27 crore
- EBITDA (FY25)
- Rs 267.8 crore
- PAT (FY25)
- Rs 134.3 crore
- EBITDA Margin (FY25)
- 20.7%
- RoNW (FY25)
- 29%
- R&D Spending (FY25)
- 10.4%
- USFDA Approved Products (June 2025)
- 81